Skip to main content

Table 4 Previous studies

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Reference N° of Pts Tumor Stage Response rate
Brausi M et al., Urology 1998 [20] 13 Ta-T1 Marker lesion 40% (at 6 months)
Di Stasi MS et al., J Urol 2003 [21] 108 BCG-naïve multifocal Cis 52.8% (at 6 months)
Sockett L et al., BJUInt 2008 [36] 13 BCG-refractory HGNMIBC 31% (at 15 months)
Riedl CR et al., J Urol 1998 [39] 16 Ta-T1 56% (at 14.1 months)
Our experience 23 BCG-refractory HGNMIBC 61.5% (at 36 months)
\